A 2017 article from "Stat News" is revisited, revealing that Moderna faced significant safety hurdles and technical failures with its mRNA technology years before the pandemic. The report suggests that the COVID-19 crisis served as a "miraculous Hail Mary" for the company, which had previously struggled to produce viable results for Wall Street investors.



